vs
Forestar Group Inc.（FOR）与Prestige Consumer Healthcare Inc.（PBH）财务数据对比。点击上方公司名可切换其他公司
Prestige Consumer Healthcare Inc.的季度营收约是Forestar Group Inc.的1.0倍（$283.4M vs $273.0M），Prestige Consumer Healthcare Inc.净利率更高（16.5% vs 5.6%，领先10.8%），Forestar Group Inc.同比增速更快（9.0% vs -2.4%），Prestige Consumer Healthcare Inc.自由现金流更多（$75.3M vs $-157.1M），过去两年Prestige Consumer Healthcare Inc.的营收复合增速更高（1.2% vs -9.6%）
福雷斯特集团是一家住宅地块开发企业，总部位于得克萨斯州阿灵顿，业务覆盖美国21个州的51个市场。截至2020年12月31日的12个月内，该公司交付了11518块住宅地块，目前在纽约证券交易所上市，自2002年起就是美国规模最大的住宅建筑商D.R. Horton的控股子公司。
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
FOR vs PBH — 直观对比
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $273.0M | $283.4M |
| 净利润 | $15.4M | $46.7M |
| 毛利率 | 20.1% | 55.5% |
| 营业利润率 | 7.6% | 29.1% |
| 净利率 | 5.6% | 16.5% |
| 营收同比 | 9.0% | -2.4% |
| 净利润同比 | -6.7% | -23.5% |
| 每股收益（稀释后） | $0.30 | $0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $273.0M | $283.4M | ||
| Q3 25 | $670.5M | $274.1M | ||
| Q2 25 | $390.5M | $249.5M | ||
| Q1 25 | $351.0M | $296.5M | ||
| Q4 24 | $250.4M | $290.3M | ||
| Q3 24 | $551.3M | $283.8M | ||
| Q2 24 | $318.4M | $267.1M | ||
| Q1 24 | $333.8M | $277.0M |
| Q4 25 | $15.4M | $46.7M | ||
| Q3 25 | $86.9M | $42.2M | ||
| Q2 25 | $32.9M | $47.5M | ||
| Q1 25 | $31.6M | $50.1M | ||
| Q4 24 | $16.5M | $61.0M | ||
| Q3 24 | $81.5M | $54.4M | ||
| Q2 24 | $38.7M | $49.1M | ||
| Q1 24 | $45.0M | $49.5M |
| Q4 25 | 20.1% | 55.5% | ||
| Q3 25 | 22.3% | 55.3% | ||
| Q2 25 | 20.4% | 56.2% | ||
| Q1 25 | 22.6% | 57.3% | ||
| Q4 24 | 22.0% | 55.5% | ||
| Q3 24 | 23.9% | 55.5% | ||
| Q2 24 | 22.5% | 54.7% | ||
| Q1 24 | 24.9% | 54.8% |
| Q4 25 | 7.6% | 29.1% | ||
| Q3 25 | 16.9% | 29.1% | ||
| Q2 25 | 11.2% | 28.8% | ||
| Q1 25 | 11.6% | 29.8% | ||
| Q4 24 | 8.7% | 31.7% | ||
| Q3 24 | 19.7% | 29.7% | ||
| Q2 24 | 16.2% | 27.0% | ||
| Q1 24 | 17.6% | 29.7% |
| Q4 25 | 5.6% | 16.5% | ||
| Q3 25 | 13.0% | 15.4% | ||
| Q2 25 | 8.4% | 19.0% | ||
| Q1 25 | 9.0% | 16.9% | ||
| Q4 24 | 6.6% | 21.0% | ||
| Q3 24 | 14.8% | 19.2% | ||
| Q2 24 | 12.2% | 18.4% | ||
| Q1 24 | 13.5% | 17.9% |
| Q4 25 | $0.30 | $0.97 | ||
| Q3 25 | $1.70 | $0.86 | ||
| Q2 25 | $0.65 | $0.95 | ||
| Q1 25 | $0.62 | $1.00 | ||
| Q4 24 | $0.32 | $1.22 | ||
| Q3 24 | $1.59 | $1.09 | ||
| Q2 24 | $0.76 | $0.98 | ||
| Q1 24 | $0.89 | $0.98 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $211.7M | $62.4M |
| 总债务越低越好 | $793.2M | $1.0B |
| 股东权益账面价值 | $1.8B | $1.8B |
| 总资产 | $3.2B | $3.5B |
| 负债/权益比越低杠杆越低 | 0.44× | 0.56× |
8季度趋势，按日历期对齐
| Q4 25 | $211.7M | $62.4M | ||
| Q3 25 | $379.2M | $119.1M | ||
| Q2 25 | $189.2M | $139.5M | ||
| Q1 25 | $174.3M | $97.9M | ||
| Q4 24 | $132.0M | $50.9M | ||
| Q3 24 | $481.2M | $51.5M | ||
| Q2 24 | $359.2M | $34.3M | ||
| Q1 24 | $416.2M | $46.5M |
| Q4 25 | $793.2M | $1.0B | ||
| Q3 25 | $802.7M | $993.1M | ||
| Q2 25 | $872.8M | $992.7M | ||
| Q1 25 | $872.5M | $992.4M | ||
| Q4 24 | $806.8M | $992.0M | ||
| Q3 24 | $706.4M | $1.1B | ||
| Q2 24 | $706.1M | $1.1B | ||
| Q1 24 | $705.7M | $1.1B |
| Q4 25 | $1.8B | $1.8B | ||
| Q3 25 | $1.8B | $1.8B | ||
| Q2 25 | $1.7B | $1.9B | ||
| Q1 25 | $1.6B | $1.8B | ||
| Q4 24 | $1.6B | $1.8B | ||
| Q3 24 | $1.6B | $1.7B | ||
| Q2 24 | $1.5B | $1.7B | ||
| Q1 24 | $1.5B | $1.7B |
| Q4 25 | $3.2B | $3.5B | ||
| Q3 25 | $3.1B | $3.4B | ||
| Q2 25 | $3.1B | $3.4B | ||
| Q1 25 | $3.0B | $3.4B | ||
| Q4 24 | $3.0B | $3.3B | ||
| Q3 24 | $2.8B | $3.3B | ||
| Q2 24 | $2.7B | $3.3B | ||
| Q1 24 | $2.6B | $3.3B |
| Q4 25 | 0.44× | 0.56× | ||
| Q3 25 | 0.45× | 0.54× | ||
| Q2 25 | 0.52× | 0.54× | ||
| Q1 25 | 0.53× | 0.54× | ||
| Q4 24 | 0.50× | 0.55× | ||
| Q3 24 | 0.44× | 0.61× | ||
| Q2 24 | 0.47× | 0.65× | ||
| Q1 24 | 0.48× | 0.68× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-157.0M | $78.3M |
| 自由现金流经营现金流 - 资本支出 | $-157.1M | $75.3M |
| 自由现金流率自由现金流/营收 | -57.5% | 26.6% |
| 资本支出强度资本支出/营收 | 0.0% | 1.1% |
| 现金转化率经营现金流/净利润 | -10.19× | 1.68× |
| 过去12个月自由现金流最近4个季度 | $93.0M | $267.2M |
8季度趋势，按日历期对齐
| Q4 25 | $-157.0M | $78.3M | ||
| Q3 25 | $256.3M | $57.5M | ||
| Q2 25 | $15.8M | $79.0M | ||
| Q1 25 | $-19.8M | $61.8M | ||
| Q4 24 | $-450.0M | $65.1M | ||
| Q3 24 | $119.2M | $69.8M | ||
| Q2 24 | $-61.7M | $54.8M | ||
| Q1 24 | $-59.2M | $66.9M |
| Q4 25 | $-157.1M | $75.3M | ||
| Q3 25 | $255.6M | $55.4M | ||
| Q2 25 | $15.0M | $78.2M | ||
| Q1 25 | $-20.5M | $58.4M | ||
| Q4 24 | — | $63.5M | ||
| Q3 24 | $118.4M | $67.8M | ||
| Q2 24 | $-62.3M | $53.6M | ||
| Q1 24 | $-59.8M | $63.8M |
| Q4 25 | -57.5% | 26.6% | ||
| Q3 25 | 38.1% | 20.2% | ||
| Q2 25 | 3.8% | 31.3% | ||
| Q1 25 | -5.8% | 19.7% | ||
| Q4 24 | — | 21.9% | ||
| Q3 24 | 21.5% | 23.9% | ||
| Q2 24 | -19.6% | 20.1% | ||
| Q1 24 | -17.9% | 23.0% |
| Q4 25 | 0.0% | 1.1% | ||
| Q3 25 | 0.1% | 0.8% | ||
| Q2 25 | 0.2% | 0.3% | ||
| Q1 25 | 0.2% | 1.2% | ||
| Q4 24 | 0.0% | 0.5% | ||
| Q3 24 | 0.1% | 0.7% | ||
| Q2 24 | 0.2% | 0.4% | ||
| Q1 24 | 0.2% | 1.1% |
| Q4 25 | -10.19× | 1.68× | ||
| Q3 25 | 2.95× | 1.36× | ||
| Q2 25 | 0.48× | 1.66× | ||
| Q1 25 | -0.63× | 1.23× | ||
| Q4 24 | -27.27× | 1.07× | ||
| Q3 24 | 1.46× | 1.28× | ||
| Q2 24 | -1.59× | 1.12× | ||
| Q1 24 | -1.32× | 1.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FOR
| D.R.Horton Inc. | $183.8M | 67% |
| Other | $89.2M | 33% |
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
